

Rutgers Cancer Institute Bone Marrow Tumor Board

Provided by Rutgers Cancer Institute, Department of Hematology

Interesting Cases of the Week

Wednesday, September 30, 2026 - 1:00-2:00 PM

Virtual: <https://rutgers.zoom.us/j/99371545348?pwd=5jRyJF1rnAIGROP5nbqmGI43O4OyHW.1>

In-Person Location Morris Cancer Institute 4th Floor Conference Room 04-135

Jaqueline Manago, RN, BSN, BMTCH, Manisha Patel, RN, BSN, Sheetal Trivedi, RN, BSN, Katelyn Gunn, RN, BSN,

Phillip Rivera, RN, BSN, Eileen Howarth, RN, BSN, Rajneesh Nath, MD, and Maria Feinstein, DNP

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Identify courses of treatments with presenting options from newly assigned guidelines by NCCN
- Analyze oncological provider's opinions to identify approaches to patient management and care.
- Discuss clinical trials' specific eligibility criteria and treatment protocols.

Target Audience

This activity is designed for medical oncologists, pharmacists, surgical oncologists, general surgeons, radiation oncologists, radiologists, hematologists, pathologists, physician assistants, nurses, and nurse practitioners involved in Bone Marrow and Stem cell transplant.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: -This activity is awarded 1 ANCC contact hour.

Pharmacists: This knowledge-based activity qualifies for 1 contact hour of continuing pharmacy education credit.

Disclosure Declarations

Jacqueline Manago, RN, BSN, BMTCH, Manisha Patel, RN, BSN, Sheetal Trivedi, RN, BSN, Katelyn Gunn, RN, BSN, Phillip Rivera, RN, BSN, Eileen Howarth, RN, BSN, Rajneesh Nath, MD, and Maria Feinstein, DNP have no relevant financial interests with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: *Activity Director:* Matthew Matasar, MD has the following relevant financial relationships with ineligible companies: Consultant: ADC Therapeutics, Allogene, Arvinas, AstraZeneca, Bristol Myers Squibb, Genentech, Genmab, Johnson & Johnson, Regeneron Pharmaceuticals, Roche; Expert Witness: Bayer; *Content Reviewers:* Michael Kane, RPH, BCOP and Jacqueline Manago, RN, BSN, BMTCH have no

relevant financial interests with ineligible companies to disclose. All of the relevant financial relationships listed have been mitigated.

Rutgers Health CE Staff: Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.